| R910190 |
anthracene-2,6-diamine |
|
| R910191 |
2,6-DIBROMOANTHRACENE |
|
| R910192 |
ly-900009 |
LY900009 is a small molecule inhibitor of Notch signalling via selective inhibit
|
| R910193 |
ly411575 |
LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.0
|
| R910194 |
N,N-dimethyl-2-oxo-1,3-dihydroindole-5-sulfonamide |
|
| R910195 |
N-(3-bromophenyl)-6-nitroquinazolin-4-amine |
|
| R910196 |
2-bromo-5-methyl-4-nitrophenol |
|
| R910197 |
3-Iodo-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
|
| R910198 |
1-BOC-5-methoxyindole-2-boronic acid |
|
| R910199 |
2,9-Bis(2,6-dimethylphenyl)isoquinolino[4',5',6':6,5,10]anthra[2, 1,9-def]isoquinoline-1,3,8,10(2H,9H)-tetrone |
|
| R910200 |
[2.2]Orthocyclophane |
|
| R910201 |
Tetraphenylmethane |
|
| R910202 |
BMS813160 |
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical de
|
| R910203 |
PF-06454589 |
PF-06454589 is a potent and selective LRRK2 inhibitor.
|
| R910204 |
BKM-120;BKM120; BKM 120; NVP-BKM120 |
BKM120 (NVP-BKM120) is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor an
|
| R910205 |
ZL0420;ZL-0420; ZL 0420 |
ZL0420 is a potent and selective BRD4 inhibitor. ZL0420 reduces airway inflammat
|
| R910206 |
HS1371;HS-1371;HS 1371 |
HS-1371 is a potent and ATP-competitive receptor-interacting protein kinase 3 (R
|
| R910207 |
IITZ-01 |
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitum
|
| R910208 |
Lidocaine Impurity 14 |
|
| R910209 |
BenzydaMine IMpurity A |
|
| R910210 |
1-BENZYL-3-(3-DIETHYLAMINO-PROPOXY)-1H-INDAZOLE |
|
| R910211 |
YHO-13177 |
YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxici
|
| R910212 |
2-HYDROXYFLUORENE |
|
| R910213 |
4,4,5,5-Tetramethyl-2-(naphthalen-2-ylmethyl)-1,3,2-dioxaborolane |
|
| R910214 |
5-hydroxy-6-methylpyrazine-2-carboxylic acid |
|
